Your search for smoking cessation returned 78 results

N-nitroso-varenicline may be associated with an increased cancer risk based on data from closely related nitrosamine compounds.

The outpatient procedure provides noninvasive magnetic stimulation to areas of the brain known to be associated with addiction.

The Nonprescription Drugs Advisory Committee (NDAC) of the Food and Drug Administration (FDA) has recommended the approval of the New Drug Application (NDA) from GlaxoSmithKline for an over-the-counter (OTC) nicotine mouth spray to aid in smoking cessation (9 to 6 vote). The nicotine mouth spray (NMS) delivers 1mg nicotine per spray; each dispenser would deliver…

According to the results of a recent review, the efficacy of nicotine replacement therapy (NRT) in achieving long-term smoking cessation varies based on NRT delivery method, dosage, and timing of initiation.

Results from a placebo-controlled study evaluating Chantix (varenicline; Pfizer) in pediatric patients 12-16 years of age showed that the smoking cessation treatment was not associated with a significant increase in abstinence rates in this patient population.

Benefits of smoking cessation medications decline over the first year.

The researchers analyzed the medical records of 56,851 new users of varenicline.

The data showed TNP was significantly more effective vs. no medication assisted quit attempts for males (odds ratio [OR] 1.37, 95% CI: 1.02, 1.83; P=0.03) but not for females (OR 0.96, 95% CI: 0.71, 1.31; P=0.82).

A clinical vignette was presented to care physicians and pulmonary medicine specialists, describing a patient with asthma and ongoing combustible cigarette use who inquired about use of electronic cigarettes as a cessation tool.

The FDA determined the benefits of this smoking cessation therapy outweighed the potential risks.